Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Buy
54
EHC Quote, Financials, Valuation and Earnings
Last price:
$108.93
Seasonality move
:
4.49%
Day range:
$107.26 - $109.72
52-week range:
$92.53 - $127.99
Dividend yield:
0.66%
P/E ratio:
19.66x
P/S ratio:
1.88x
P/B ratio:
4.47x
Volume:
839.4K
Avg. volume:
1.4M
1-year change:
10.67%
Market cap:
$10.9B
Revenue:
$5.9B
EPS (TTM):
$5.54
Analysts' Opinion
-
Consensus RatingEncompass Health Corp. has received a consensus rating of Buy. The company's average rating is a Buy based on 11 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $142.73, Encompass Health Corp. has an estimated upside of 31% from its current price of $108.95.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $130.00 representing 100% downside risk from its current price of $108.95.
Fair Value
-
According to the consensus of 11 analysts, Encompass Health Corp. has 31% upside to fair value with a price target of $142.73 per share.
EHC vs. S&P 500
-
Over the past 5 trading days, Encompass Health Corp. has overperformed the S&P 500 by 2.8% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Encompass Health Corp. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Encompass Health Corp. has grown year-over-year revenues for 14 quarters straight. In the most recent quarter Encompass Health Corp. reported revenues of $1.5B.
Earnings Growth
-
Encompass Health Corp. has grown year-over-year earnings for 8 quarters straight. In the most recent quarter Encompass Health Corp. reported earnings per share of $1.43.
Enterprise value:
14.3B
EV / Invested capital:
2.39x
Price / LTM sales:
1.88x
EV / EBIT:
13.58x
EV / Revenue:
2.41x
PEG ratio (5yr expected):
0.81x
EV / Free cash flow:
32.56x
Price / Operating cash flow:
25.35x
Enterprise value / EBITDA:
10.36x
Gross Profit (TTM):
$1.3B
Return On Assets:
11.18%
Net Income Margin (TTM):
12.78%
Return On Equity:
24.73%
Return On Invested Capital:
13.16%
Operating Margin:
18.35%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Income Statement | ||||||
| Revenue | $4.8B | $5.4B | $5.9B | $1.4B | $1.5B | |
| Gross Profit | $933.5M | $1.1B | $1.3B | $286.8M | $351.8M | |
| Operating Income | $731.8M | $864.5M | $1.1B | $232.3M | $283.4M | |
| EBITDA | $1B | $1.2B | $1.4B | $310.3M | $369.8M | |
| Diluted EPS | $3.48 | $4.46 | $5.54 | $1.18 | $1.43 | |
| Period Ending | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $921.4M | $717.2M | $841.8M | $886.9M | $905.9M | |
| Total Assets | $6.9B | $5.6B | $6.1B | $6.5B | $7.1B | |
| Current Liabilities | $748.8M | $575.9M | $656.4M | $841M | $836.4M | |
| Total Liabilities | $4.5B | $3.8B | $3.8B | $3.7B | $3.8B | |
| Total Equity | $2.4B | $1.9B | $2.3B | $2.8B | $3.3B | |
| Total Debt | $3.5B | $3B | $2.9B | $2.7B | $2.7B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-31 | 2024-12-31 | 2025-12-31 | 2024-12-31 | 2025-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $850.8M | $1B | $1.2B | $278.8M | $346M | |
| Cash From Investing | -$534.5M | -$512.9M | -$762.8M | -$203M | -$237.6M | |
| Cash From Financing | -$265.5M | -$471M | -$433M | -$151.6M | -$99.2M | |
| Free Cash Flow | $267.7M | $360.3M | $439.2M | $80.1M | $116.7M | |
EHC
Sector
Market Cap
$10.9B
$25.3M
Price % of 52-Week High
85.12%
49.41%
Dividend Yield
0.66%
0%
Shareholder Yield
2.31%
-1.6%
1-Year Price Total Return
10.67%
-17.71%
Beta (5-Year)
0.727
0.490
Dividend yield:
0.66%
Annualized payout:
$0.70
Payout ratio:
13.27%
Growth streak:
1 years
Technicals
8-day SMA
Buy
Level
$107.15
200-day SMA
Sell
Level
$114.99
Bollinger Bands (100)
Sell
Level
101.84 - 118.52
Chaikin Money Flow
Buy
Level
215M
20-day SMA
Buy
Level
$107.05
Relative Strength Index (RSI14)
Buy
Level
60.06
ADX Line
Buy
Level
33.12
Williams %R
Neutral
Level
-54.5772
50-day SMA
Buy
Level
$104.03
MACD (12, 26)
Buy
Level
1.38
25-day Aroon Oscillator
Buy
Level
12
On Balance Volume
Neutral
Level
158.5M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.2635)
Buy
CA Score
(Annual)
Level (-0.2036)
Buy
Beneish M-Score
(Annual)
Level (-2.8907)
Buy
Momentum Score
Level (4)
Buy
Ohlson Score
Level (-0.8491)
Buy
Piotroski F Score
(Annual)
Level (9)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (10)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Encompass Health Corp. engages in the provision of post-acute healthcare services. It provides specialized rehabilitative treatment on an inpatient basis. The company was founded by Richard M. Scrushy on February 22, 1984 and is headquartered in Birmingham, AL.
Stock Forecast FAQ
In the current month, EHC has received 11 Buy ratings 0 Hold ratings, and 0 Sell ratings. The EHC average analyst price target in the past 3 months is $142.73.
-
Where Will Encompass Health Corp. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Encompass Health Corp. share price will rise to $142.73 per share over the next 12 months.
-
What Do Analysts Say About Encompass Health Corp.?
Analysts are divided on their view about Encompass Health Corp. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Encompass Health Corp. is a Sell and believe this share price will drop from its current level to $130.00.
-
What Is Encompass Health Corp.'s Price Target?
The price target for Encompass Health Corp. over the next 1-year time period is forecast to be $142.73 according to 11 Wall Street analysts, 11 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is EHC A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Encompass Health Corp. is a Buy. 11 of 11 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of EHC?
You can purchase shares of Encompass Health Corp. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Encompass Health Corp. shares.
-
What Is The Encompass Health Corp. Share Price Today?
Encompass Health Corp. was last trading at $108.93 per share. This represents the most recent stock quote for Encompass Health Corp.. Yesterday, Encompass Health Corp. closed at $108.95 per share.
-
How To Buy Encompass Health Corp. Stock Online?
In order to purchase Encompass Health Corp. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get EHC Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
EHC
Sector
P/E ratio
19.66x
22.85x
PEG ratio
0.81x
-0.01x
P/B ratio
4.47x
1.78x
Price / LTM sales
1.88x
1.52x
Growth Metrics
EHC
Sector
Revenue growth
9.94%
3.33%
Earnings growth
21.21%
11.64%
Revenue (5-year growth)
5.03%
6.41%
Earnings forecast
$1.30
-$0.20
Profitability
EHC
Sector
Profitability FY 2025
$1.3B
$2.3M
Return on invested capital
13.16%
-33.31%
Return on assets
11.18%
-29.79%
Return on equity
24.73%
-38.98%
Earnings Date
Last Earnings Date
Feb
5
Next Earnings Date
Apr
23
Estimated Next Earnings Date
May
7
Balance Sheet
EHC
Sector
Total cash
$145.1M
$24.1M
Short term investments
--
$23.8M
Total assets
$7.1B
$70.1M
Long term debt
$2.7B
$2.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
49
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 37x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
42
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Sell
46
ZD alert for Mar 5
Ziff Davis, Inc. [ZD] is up 3.64% over the past day.
Sell
37
PSIX alert for Mar 5
Power Solutions International, Inc. [PSIX] is down 1.4% over the past day.
Sell
49
TREE alert for Mar 5
LendingTree, Inc. [TREE] is up 1.11% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
